drugset / Trial / NCT00358566
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Phase 3
Terminated
360 enrolled
Pharmexa A/S
CIRION Central Laboratory · collabDorevitch · collabICON Clinical Research · collabORION Clinical Services · collabSyneos Health · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally advanced and metastatic adenocarcinoma of the pancreas.
Timeline
- Start
- 2006-06
- Primary completion
- 2008-08
- Completion
- 2008-08
Outcome
Outcome not reported
Stopped: “Preliminary data showed no survival benefit in the GV1001 group compared to the gemcitabine group.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | TERTOMOTIDE | Vaccine | 0.56 mg | — |